<i id='8E1959ED89'><strike id='8E1959ED89'><tt id='8E1959ED89'><pre id='8E1959ED89'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Alkermes shareholders re 
Surprise medical billing ban raises prices elsewhere 
Trump demands the U.S. pay no more for drugs than other countries … again 
Threats against the LGBTQIA+ community intensifying: Department of Homeland Security 
Medicare proposal to cover medical devices draws a mixed reaction 
Ukraine seeks to reclaim its role as a hub for clinical trials 
BioMarin wins approval for gene therapy to treat hemophilia A 
FDA warns medical device makers about rise in fabricated data
BioMarin wins approval for gene therapy to treat hemophilia A 
Medicare Advantage enrollment hits roughly 33.4 million 
George Santos makes 1st court appearance after pleading not guilty to 13 counts
Medicare Advantage enrollment hits roughly 33.4 million 
Medical records are filled with copy 
Why ADHD is under
Medicare proposal to cover medical devices draws a mixed reaction 
